Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
Become part of the elite network of practitioners leveraging RGCC's groundbreaking technologies to transform patient outcomes. Our comprehensive testing is helping practitioners develop more personalized, effective treatment plans for their patients at each step of the cancer journey.
We equip practitioners with advanced cancer diagnostic tools that go beyond conventional approaches. By becoming a registered RGCC practitioner, you'll differentiate your practice with cutting-edge technology while providing patients with personalized treatment plans based on their unique cancer profiles.
Our practitioner network connects you with a global community of forward-thinking professionals, ongoing education, and dedicated support to help you implement these advanced solutions effectively.
With our comprehensive approach to cancer diagnostics, you'll be able to offer patients earlier detection, more precise therapies, and better monitoring than ever before.
As an RGCC practitioner, you'll gain access to diagnostic capabilities that fundamentally transform your ability to provide personalized cancer care. Our proprietary testing platform delivers actionable intelligence that elevates your clinical decision-making and treatment planning.
RGCC College is an educational curriculum that aims to properly equip healthcare practitioners with the skills and knowledge necessary to become registered RGCC practitioners.
All prospective practitioners are required to submit their credentials for accreditation. At RGCC, we maintain rigorous vetting standards for all incoming practitioners, ensuring the highest quality of care for patients.
Training consists of live sessions with our clinical team, during which you will gain comprehensive knowledge of our testing and therapy options tailored to meet the needs of your practice.
Gain access to exclusive documentation available only to RGCC practitioners, as well as our comprehensive online educational platform. This platform is designed not only to enhance and sustain clinical knowledge but also to train both clinical and administrative staff.
RGCC isn't just better testing—it's a complete ecosystem designed to transform how you approach personalized cancer care. Join our extensive network of practitioners who are already experiencing the benefits of RGCC partnership.
We've designed our onboarding process to be efficient and respectful of your busy schedule. Becoming an RGCC practitioner takes as little as 5 business days from start to finish, allowing you to quickly integrate our advanced testing and therapies into your practice.
Potential practitioners that have expressed interest either through an Account Manager, RGCC contact form, conferences, podcasts, or an existing practitioner, will receive via email the RGCC vetting form, which is required to be completed by all onboarding practitioners.
After vetting is successfully completed, practitioners are then emailed a list of training links to schedule their RGCC live training sessions. The training sessions each practitioner is required to take depends on their area of interest or expertise.
There are a total of 4 onboarding training sessions for a total of 4½ hours of required live training. These training sessions occur and recur every single week at the same time. These sessions must be attended in the following order.
Once all sessions have been attended, we will send out official RGCC practitioner credentials, along with a certificate of completion, an RGCC practitioner badge, an invitation to join our exclusive RGCC Facebook community group, sharing insights and helping one another within the RGCC Practitioner Community, along with regular invites to join our live practitioner roundtable discussions.
With credentials assigned, practitioners are able to place test and therapy orders, and gain exclusive access to all of our personalized support services.
Joining our network means more than just access to advanced testing—it means becoming part of a community with robust support systems designed to help you succeed. Our practitioners consistently tell us that our ongoing support is what truly sets us apart.
Our dedicated Customer Relations team serves as your first point of contact for all administrative needs, ensuring your practice operates smoothly with RGCC testing services. From tracking orders to scheduling consultations, we handle the details so you can focus on patient care.
Our Customer Relations team is available Monday through Friday, 8am - 5pm MST
Benefits for an in-depth understanding of RGCC tests and therapies, complementary training program via live training, and ongoing clinical support, including one-on-one mentoring options.
RGCC has several advantages over other cancer labs, making it a strong option for personalized cancer diagnostics:
RGCC offers a wide range of tests, including genetic, epigenetic, and proteomic analyses, providing a more comprehensive profile of a patient's cancer. This allows for a deeper understanding of the cancer's behavior and potential treatment responses.
RGCC uses various types of analyses, such as circulating tumor cells (CTCs) and cancer stem cells (CSCs) to provide a holistic view of the cancer. This multi-modal approach can offer more detailed insights compared to other lab’s focus on ctDNA alone.
RGCC's tests are designed to help create personalized treatment plans based on the unique genetic makeup of a patient's tumor. This can lead to more tailored and effective treatment strategies.
RGCC's liquid biopsy approach allows for early detection of cancer and continuous monitoring of disease progression. This can be crucial for timely intervention and effective treatment.
Overall, our comprehensive and multi-modal approach, combined with focus on personalized treatment plans and early detection, makes it a strong competitor to other cancer labs.
In 2004, genetics pioneer Dr. Ioannis Papasotiriou founded RGCC with a steadfast commitment to personalized cancer care. Driven by his unwavering belief in the power of a patient's genes, Dr. Papasotiriou's dedication and expertise have enabled RGCC to stand at the forefront of cancer treatment, providing hope and healing to patients and their families around the world.
“RGCC Cancer Testing has totally revolutionized our understanding of a client’s particular cancer.
With RGCC’s advanced testing, we are now able to create personalized cancer treatment protocols for each patient.”
"RGCC's sensitive cell count test identified my patient's circulating malignant breast cancer cells. "
"I ordered OncoTrace and Onconomics Plus to customize a plan for secondary prevention and to help with recovery from her treatment."
View Practitioner Testimonials
"For my clients, I see a massive difference as I partner with RGCC assessments and walk them through resolving trauma and unresolved stress patterns."
Discover the pulse of RGCC’s impact on the future of healthcare! Stay informed about our events, conferences, podcasts, and videos! Don't miss out on an opportunity to connect, learn, and engage with our team.
No, all RGCC tests are currently ordered by registered practitioners. Our Customer Relations team is happy to provide you with practitioners in your area. Please contact us.
Our tests can be utilized for all types of hematological and solid cancers, at various stages, outside of brain tumors because of the blood brain barrier not allowing the cells into general circulation.
Please see our published research articles, here: https://rgcc-international.com/published-articles/
RGCC is always happy to provide referrals to other RGCC practitioners in your or your patients' area. These practitioners are able to assist with phlebotomy and therapy administration if needed.
All test results are posted to your RGCC Practitioner Portal approximately 2 weeks from the time the blood arrives at the lab (and 3-4 weeks for ArrayCGH RGCC tests).
Yes! RGCC’s supply orders can be drop-shipped directly to your patient if they are located away from your office. RGCC can also provide practitioner referrals for phlebotomy if needed - just contact our customer relations team!
Yes! RGCC North America has a private, practitioners-only Facebook group. This is a great place to read, share, and ask questions brought forth by the practitioner community as well get direct feedback from RGCC’s clinicians.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
